scholarly journals Effect of Azilsartan on Day-to-Day Variability in Home Blood Pressure: A Prospective Multicenter Clinical Trial

2017 ◽  
Vol 9 (7) ◽  
pp. 618-623 ◽  
Author(s):  
Toru Miyoshi ◽  
Ryoji Suetsuna ◽  
Naoto Tokunaga ◽  
Masayasu Kusaka ◽  
Ryuichiro Tsuzaki ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Clinical Trial ◽  
Home Blood Pressure ◽  
Multicenter Clinical Trial

A Prospective Multicenter Clinical Trial of Chinese Herbal Formula JZQG (Jiangzhuoqinggan) for Hypertension

2013 ◽  
Vol 41 (01) ◽  
pp. 33-42 ◽  
Author(s):  
Xiao-Lin Tong ◽  
Feng-Mei Lian ◽  
Qiang Zhou ◽  
Li-Peng Xu ◽  
Hang-Yu Ji ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Clinical Trial ◽  
Waist Circumference ◽  
Ambulatory Blood Pressure ◽  
Blood Pressure Measurement ◽  
Multicenter Clinical Trial ◽  
Beneficial Effects ◽  
Chinese Herbal ◽  
Significant Difference ◽  
Blood Pressures

A prospective multicenter clinical trial was conducted to compare the beneficial effects of a Chinese herbal medicine formula Jiangzhuoqinggan (JZQG) and western antihypertension drug irbesartan. JZQG is mainly composed of rhubarb, coptis, cassia, and uncaria. A total of 240 patients with mild to moderate hypertension were enrolled in the trial. Patients were assigned into two groups after screening: JZQG group and the irbesartan group. After four weeks of treatment, we compared the changes in routine blood pressure, 24 h ambulatory blood pressure, and waist circumference. There was a significant reduction in systolic blood pressure and diastolic blood pressure in the JZQG group (both p < 0.01). There were no significant differences between the reduction of systolic and diastolic blood pressures in the two treatment groups. From the 24 h ambulatory blood pressure measurement, the JZQG group showed a greater reduction in both systolic and diastolic blood pressures (in both daytime and nighttime) than the irbesartan group. Furthermore, there was a significant difference in waist circumference in the JZQG group (1.51 cm reduction; P < 0.05) but not the irbesartan group (0.42 cm). Thus, the JZQG formula may have therapeutic value in patients with both hypertension and metabolic syndrome.

scholarly journals Home blood pressure monitors owned by participants in a large decentralised clinical trial in hypertension: the Treatment In Morning versus Evening (TIME) study

2021 ◽  
Author(s):  
Thineskrishna Anbarasan ◽  
Amy Rogers ◽  
David A. Rorie ◽  
J. W. Kerr Grieve ◽  
Thomas M. MacDonald ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Clinical Trial ◽  
Antihypertensive Medication ◽  
Randomised Trial ◽  
Home Blood Pressure ◽  
Retail Price ◽  
Time Study ◽  
Online Retail ◽  
The Public ◽  
Blood Pressure Monitors

AbstractVarious home blood pressure monitors (HBPMs) are available to the public for purchase but only some are validated against standardised protocols. This study aimed to assess whether HBPMs owned by participants taking part in a clinical trial were validated models. The TIME study is a decentralised randomised trial investigating the effect of antihypertensive medication dosing time on cardiovascular outcomes in adults with hypertension. No HBPMs were provided to participants in this trial but patients were asked to report if they already owned one. We identified the model of HBPM reported by participants, then cross-referenced this against lists of validated HBPMs produced by dabl Educational Trust and the British and Irish Hypertension Society (BIHS). Of 21,104 participants, 10,464 (49.6%) reported their model of HBPM. 7464 (71.3%) of these participants owned a monitor that could be identified from the participants’ entry. Of these, 6066 (81.3%) participants owned a monitor listed as validated by either dabl (n = 5903) or BIHS (n = 5491). Some were listed as validated by both. 1398 (18.7%) participants owned an identifiable HBPM that lacked clear evidence of validation. 6963 (93.3%) participants owned an upper arm HBPM and 501 (6.7%) owned a wrist HBPM. Validated HBPMs had a higher median online retail price of £45.00 compared to £20.00 for HBPMs lacking clear evidence of validation. A significant number of participants own HBPMs lacking evidence of validation.

scholarly journals Preliminary Experiment on the Effect of 18% Substitute Salt on Home Blood Pressure Variability in Hypertensives

2021 ◽  
Vol 2021 ◽  
pp. 1-6
Author(s):  
Jing Li ◽  
Lisha Mu ◽  
Huakun Rao ◽  
Yangfeng Wu ◽  
Hao Wang ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Clinical Trial ◽  
Adverse Events ◽  
Phase I ◽  
Blood Pressure Variability ◽  
Sodium Intake ◽  
Home Blood Pressure ◽  
Intervention Period ◽  
Over Time

At present, the effect of substitute salt in reducing sodium intake and blood pressure is relatively clear. The present study is a phase I clinical trial involving 43 hypertensives in which the effect of 18% sodium substitute salt on the home blood pressure variability (BPV) was observed for 8 weeks with weekly follow-up. Finally, 4 patients were lost, and 39 patients completed the intervention and were included in the analysis. Daily home blood pressure and weekly adverse events were collected. The systolic blood pressure (SBP) in the morning (−10.0 mmHg, 95% CI: −16.5 to −3.5, P  = 0.003), SBP at night (−10.2 mmHg, 95% CI: −16.1 to −4.3, P  = 0.001), and diastolic blood pressure (DBP) at night (−4.0 mmHg, 95% CI: −7.1 to −0.8, P  = 0.014) decreased significantly. Also, there was no statistically significant change in morning (F = 1.137, P  = 0.352) and night diastolic (F = 0.344, P  = 0.481) BPV and morning systolic BPV (F = 0.663, P  = 0.930) over time during the intervention period, except for that night systolic BPV had a downward trend (F = 2.778, P  = 0.016) and had decreased 2.04 mmHg (95% CI: 0.84 to 3.23, P  = 0.001) after intervention. The use of 18% of the substitute salt did not increase BPV during the intervention and even may decrease it, which indicates its control effects on blood pressure. This study is the first one to observe the effect of 18% sodium substitute salt on the home blood pressure variability, providing a basis for further experiments.

scholarly journals Antihypertensive drug effects according to the pretreatment self-measured home blood pressure: the HOMED-BP study

BMJ Open ◽  
2020 ◽  
Vol 10 (12) ◽  
pp. e040524
Author(s):  
Hikari Sano ◽  
Azusa Hara ◽  
Kei Asayama ◽  
Seiko Miyazaki ◽  
Masahiro Kikuya ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Clinical Trial ◽  
Antihypertensive Drug ◽  
Low Dose ◽  
Antihypertensive Drugs ◽  
Home Blood Pressure ◽  
Fixed Dose ◽  
Defined Daily Dose ◽  
Regression To The Mean ◽  
Clinical Trial Registry

ObjectivesTo clarify whether or not the antihypertensive drug effect is proportional to the baseline pretreatment self-measured home blood pressure (HBP) in accordance with the law of initial value (Wilder’s law).DesignA post-hoc analysis of a multicentre clinical trial.SettingOutpatients across Japan with mild-to-moderate essential hypertension.ParticipantsAmong 3518 randomised participants, 2423 who self-measured HBP during the pretreatment drug-free period (10–28 days after starting fixed-dose antihypertensive monotherapy) with a mean 7.0 years follow-up were eligible.Main outcome measuresWe analysed individual HBP readings during pretreatment and monotherapy.ResultsThe day-to-day HBP during both the pretreatment period and monotherapy period remains almost the same throughout each period; the results were consistent, regardless of the pretreatment HBP. Following monotherapy, the reduction in the HBP increased by 2.2 mm Hg (95% CI: 1.8 to 2.5 mm Hg) per 10 mm Hg pretreatment HBP increase, up to 11.0 mm Hg (95% CI: 9.9 to 12.0 mm Hg) among patients with an HBP ≥165 mm Hg during pretreatment. Among the 1005 patients receiving low-dose monotherapy (defined daily dose: 0.5 units), the reduction peaked at 8.9–9.1 mm Hg in those with pretreatment HBP 155–164 mm Hg and ≥165 mm Hg (p=0.88).ConclusionsAccording to Wilder’s law, the HBP reduction due to fixed-dose monotherapy was proportional to the pretreatment HBP without any regression to the mean phenomenon. With low-dose antihypertensive drugs, however, the HBP reduction peaked in patients with a high pretreatment HBP, indicating the need for such patients to receive a sufficient amount of antihypertensive drug medication at the initial treatment.Trial registrationUMIN Clinical Trial Registry (http://www.umin.ac.jp/ctr), Unique identifier: C000000137.

Sign in / Sign up

Export Citation Format

Share Document